We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. The 15-day Dexcom G7 had a MARD of 8%, a small ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved extending the use of an implantable continuous glucose monitoring sensor for up to 6 months ...

Early proof-of-concept study showed that a patch pump with integrated glucose sensing at the site of insulin delivery can ...

DexCom, Inc. DXCM recently unveiled new data for its upcoming G7 15-day continuous glucose monitoring (CGM) sensor at the Advanced Technologies & Treatments for Diabetes (ATTD) conference 2025. With ...

Diabetes remains one of the nation’s most prevalent and dangerous chronic conditions, affecting nearly 15% of U.S. adults and causing more than 100,000 deaths each year. As a response, the landscape ...

The next-generation CGM is now available in Sweden, with launches expected in Germany, Spain and Italy during the coming weeks as part of a ...

The US Food and Drug Administration has cleared the Dexcom G7 15-Day Continuous Glucose Monitor (CGM) for people older than 18 with diabetes. It's the longest-lasting system on the market. The G7 ...

This morning Belgian startup Indigo Diabetes announced a €38 million ($44.6 million) Series B funding round. This round included contributions from new investors Fund+, Ackermans&van Haaren, Capricorn ...

The FDA has issued a class two device recall for Senseonics’ Eversense continuous glucose monitoring system. This posting follows a September notice from the company that alerted providers and ...

Concerns over Abbott's glucose monitoring devices highlight the urgent need for improved customer complaint redressal ...